Ownership Breakdown
| Retail Investors74.82% | Insiders22.8% |
| Retail Investors | 74.82 | |
| Insiders | 22.8 | |
| Institutions | 2.38 |
Will Aptorum (USA Stocks:APM) turn things around in October?
 | By Gabriel Shpitalnik | Macroaxis Story |
Approximately 23.0% of Aptorum Group's shares are held by company insiders. The insider ownership of Aptorum Group pertains to the portion of the company's equity owned by its officers, directors, relatives of the leadership team, or anyone who has access to non-public information. For our latest analysis of Aptorum, including its current ownership diagnostics, please check out our most recent report.
Extended review
Investing in Aptorum Group stock can be viewed as a promising venture from a product viewpoint. The company, which operates in the biotechnology industry, has a strong product pipeline that is underpinned by a robust research and development strategy. However, the company's financial performance has been a bit of a mixed bag. Aptorum Group reported a revenue of 1.3 million dollars and a revenue per share of 0.36 dollars. Unfortunately, the company has also reported a loss, with a diluted EPS of 2.56 dollars and an EPS estimate for the current year at a loss of 0.64 dollars. Despite this, the company's total risk alpha of 0.11 suggests that the company's stock has the potential to provide a higher return for a given level of risk compared to other stocks. The potential upside of 9.78% also indicates that the stock could be poised for a breakout. However, investors should be aware of the company's Jensen Alpha of -0.1, which suggests that the company's actual return has fallen short of its expected return.Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Michael Smolkin
Aptorum Group, a notable player in the Healthcare sector and specifically in the Biotechnology service category, has been catching the eyes of investors recently. The company, which is listed on the NASDAQ and is not delisted, has been showing promising signs of a potential breakout. Despite reporting a loss of $0.84 per share in the next year's EPS estimate and a current quarter EPS estimate of $0.27, the company has managed to maintain a book value of 4.4. Aptorum Group's revenue per share stands at 0.363, and it has managed to keep its selling and marketing expenses at a modest 98.1K. Interestingly, the company has an analyst overall consensus of a 'Strong Buy' with one analyst giving a strong buy recommendation. The estimated target price stands at a whopping $80, indicating a possible upside despite a downside price of 0.0227. The valuation hype value of the company is 2.27, while the real value is 21.61. As of the last update on 2023-09-24, the company had an interest income of 146.6K and an income tax expense of 6.2M. The Tangible Asset Value of Aptorum Group is currently very stable, showing a significant improvement from the previous year. Last year, Aptorum reported a Tangible Asset Value of $20.11 million. As of September 30, 2023, the company's Book Value per Share is projected to increase to $5.86, while its Earnings Before Tax are expected to decrease to -$10.6 million.
As the biotechnology sector continues to pique the interest of many millennials, it is only appropriate to reevaluate Aptorum Group. In this article, we will delve into why this could be a more prosperous year for Aptorum shareholders. We will explore various fundamental factors that influence Aptorum's products and services, and how these could potentially affect the investment outlook for Aptorum in October.The performance of Aptorum Group Ltd in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Aptorum Group's stock prices. When investing in Aptorum Group, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Aptorum Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Aptorum Group carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.
Watch out for price decline
Please consider monitoring Aptorum Group on a daily basis if you are holding a position in it. Aptorum Group is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Aptorum Group stock to be traded above the $1 level to remain listed. If Aptorum Group stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Aptorum Group's Liquidity
Aptorum Group financial leverage refers to using borrowed capital as a funding source to finance Aptorum Group Ltd ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Aptorum Group financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Aptorum Group's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Aptorum Group's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Aptorum Group's total debt and its cash.
Aptorum Group Gross Profit
Aptorum Group Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Aptorum Group previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Aptorum Group Gross Profit growth over the last 10 years. Please check Aptorum Group's gross profit and other fundamental indicators for more details.
Going after Aptorum Financials
Aptorum Group retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months.
Aptorum Group, a biotechnology company based in 17 Hanover Square, London, United Kingdom, is showing signs of potential breakout. Despite a net income loss of $11.5M and an EBITDA loss of $16.3M, the company's total assets stand at a healthy $20.87M. Aptorum Group's book value is 4.4, with a price to book ratio of 0.80X, indicating that the stock is currently undervalued. The company's total debt is manageable at $6.85M, representing a debt to equity ratio of 0.23%.The company's shares are primarily held by insiders, with 22.80% of shares owned by insiders and 2.38% owned by institutions. Despite a short ratio of 1.07X, only 29.3K shares are shorted, suggesting that the market sentiment is generally positive. The Wall Street target price for the stock is a whopping $80, indicating a significant potential upside. Despite the company's current valuation of $4.7M, its market capitalization is only $9.39M, suggesting that the stock is undervalued. Aptorum Group's revenue per share is 0.363, with a price to sales ratio of 12.47X. The company's operating margin is -13.51, indicating that it is currently operating at a loss. However, with a potential upside of 9.78, Aptorum Group's stock may be poised for a breakout. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Aptorum Group Ltd. Please refer to our Terms of Use for any information regarding our disclosure principles.